Related Experiment Videos
Developmental toxicity of valproic acid
1Department of Biochemical Pathology, Assaf Harofeh Medical Center, Sackler School of Medicine, Tel Aviv University, Zerifin, Israel.
Insights
Valproic acid, an epilepsy medication, increases birth defects in infants. Research explores its placental transfer, teratogenic potential, and effects on fetal development.
Area of Science:
- Pharmacology
- Developmental Toxicology
- Teratology
Background:
- Valproic acid is a key anticonvulsant for epilepsy management.
- Prenatal exposure to valproic acid is linked to congenital abnormalities.
Purpose of the Study:
- To review current knowledge on valproic acid's role in prenatal growth impairment.
- To summarize clinical and research findings on valproic acid teratogenicity.
Main Methods:
- Literature review of clinical studies and experimental research.
- Analysis of placental transfer, teratogenic potential, and dose-response relationships.
- Examination of species differences and fetal biochemical changes.
Main Results:
- Valproic acid readily crosses the placenta.
- Evidence supports its teratogenic potential with dose-dependent effects.
- Species and strain variations influence susceptibility to valproic acid's effects.
Conclusions:
- Valproic acid exposure during pregnancy poses significant risks for congenital abnormalities.
- Understanding these risks is crucial for managing epilepsy in pregnant individuals.
- Further research is needed to elucidate biochemical mechanisms and mitigate adverse effects.
Abstract:
Valproic acid is a very effective anticonvulsant agent widely used in the management of various forms of epilepsy. Administration of the drug during pregnancy results in increased incidence of congenital abnormalities in both humans and experimental animals. In recent years, a significant number of research efforts have attempted to define the contributory role of valproic acid to the impairment of normal prenatal growth and development. The present report summarizes current knowledge that has emerged from clinical and research studies. The specific topics include: the placental transfer of valproic acid; the teratogenic potential; structure-teratogenicity and dose-response relationships; species and strain differences; biochemical changes evoked by the drug in the fetus.